INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Pelish Henry E. sold NUVL

Chief Scientific Officer · Nuvalent, Inc. · Class A Common Stock

Side
SELL
Value
$30K
Shares
306
Price
$99.12
Executed
Mar 12, 2026
Disclosed
Mar 16, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 12 executedMar 16, 2026 disclosed

NUVL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
15/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $30K reported value · 0.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NUVL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    OJ
    Oliger Christy J.Director
    NUVLNuvalent, Inc.
    Grant or award
    		A—
    3,444 sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    0
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M$176K
    9,315 sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    0
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M$11K
    10.0K sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    25
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.46M
    20.0K sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    0
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M—
    10.0K sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    0
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M$4,720
    685 sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M—
    9,315 sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    0
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M—
    685 sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    17
    PR
    Porter James RichardDirector, President and CEO
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.28M
    14.5K sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    0
    PR
    Porter James RichardDirector, President and CEO
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M—
    30.0K sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    2
    PR
    Porter James RichardDirector, President and CEO
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M$568K
    30.0K sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    17
    PR
    Porter James RichardDirector, President and CEO
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.10M
    12.5K sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    14
    PR
    Porter James RichardDirector, President and CEO
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$272K
    3,036 sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    14
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$138K
    1,300 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    14
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$127K
    1,178 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    14
    MA
    Miller Deborah AnnChief Legal Officer
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$97K
    900 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    14
    MA
    Miller Deborah AnnChief Legal Officer
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$164K
    1,530 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MA
    Miller Deborah AnnChief Legal Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M$38K
    5,500 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    14
    MA
    Miller Deborah AnnChief Legal Officer
    NUVLNuvalent, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$149K
    1,401 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    2
    ND
    Noci DarleneChief Development Officer
    NUVLNuvalent, Inc.
    Option exercise · 10b5-1 plan
    		M$153K
    5,500 sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002029477-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 12, 2026
    Published
    Mar 16, 2026
    Ingested by INSIDER
    Nov 5, 04:11 UTC
    Last re-read
    Nov 5, 04:11 UTC

    Extracted facts

    Filer
    Pelish Henry E.
    Role
    Chief Scientific Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Nuvalent, Inc.
    Ticker
    NUVL
    Shares
    306
    Price per share
    $99.12
    Value
    $30,331
    Execution date (reported)
    Mar 12, 2026
    Owned after transaction
    70.7K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 306
    • Price: $99.12

    = $30,331

    What this establishes

    Pelish Henry E. filed this Form 4 reporting a open-market sale of NUVL on Mar 12, 2026. It became public on Mar 16, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Pelish Henry E.cik:0002029477
    Issuer
    Nuvalent, Inc.cik:0001861560

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.